- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ADAC secures Japanese clearances
Regulatory clearances obtained in late September will enable Sumitomo Metal Industries, the exclusive sales agent for ADACLaboratories in Japan, to begin selling several dual-head gammacameras designated for export to Japan by the Milpitas, CA, company.
Regulatory clearances obtained in late September will enable Sumitomo Metal Industries, the exclusive sales agent for ADACLaboratories in Japan, to begin selling several dual-head gammacameras designated for export to Japan by the Milpitas, CA, company.
The Japanese Ministry of Health and Welfare approved applicationsfor ADAC's Vertex Plus, Solus, and Cardio nuclear imaging systems.The ministry also cleared Molecular Coincidence Detection, ADAC'shigh-energy imaging technique.
Vertex Plus is ADAC's premium variable-angle camera, Solusis a fixed 180° dual-head optimized for oncology, and Cardiois a fixed 90° dual-head system devoted to cardiology.
The approval of MCD was the first of its kind for a high-energyimaging system in Japan, according to ADAC officials. ADAC's optionalMCD feature enables Vertex and Solus gamma cameras to performcoincidence-based fluorodeoxyglucose (FDG) imaging with a SPECTcamera.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
